Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

HKG:6990 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	2,776	3,244	1,337	1,529	92.96	81.79
Short-Term Investments	122.88	292.57	283.98	325.87	-	-
Trading Asset Securities	1,879	935.31	1,448	633.71	-	-
Cash & Short-Term Investments	4,778	4,472	3,069	2,488	92.96	81.79
Cash Growth	5.83%	45.71%	23.33%	2576.80%	13.65%	-
Accounts Receivable	276.69	97.27	60.76	1.35	61.8	22.73
Other Receivables	143.71	193.42	183.33	123.1	42.63	47.83
Receivables	420.4	290.69	244.09	124.45	104.43	70.56
Inventory	272.31	240.94	110.51	63.03	52.64	50.72
Prepaid Expenses	-	-	2.09	35.65	-	-
Other Current Assets	41.78	145.32	67.33	96.01	82.29	95.27
Total Current Assets	5,512	5,149	3,493	2,807	332.32	298.34
Property, Plant & Equipment	737.55	758.5	758.11	692.73	647.82	474.17
Long-Term Investments	68.12	70.08	-	-	-	-
Other Intangible Assets	0.16	1.1	2.58	1.34	3.18	0.49
Other Long-Term Assets	3.81	10.23	14.51	8.2	9.83	39.97
Total Assets	6,322	5,989	4,268	3,510	993.15	812.96

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	515.19	426.45	291.29	404.38	327.46	325.28
Accrued Expenses	141.49	184.53	156.34	133.77	86.61	44.72
Short-Term Debt	-	-	-	-	2,891	2,388
Current Portion of Leases	34.05	44.4	41.84	54.41	82.26	1.66
Current Income Taxes Payable	5.55	10	5.46	3.73	2.7	2.52
Current Unearned Revenue	168.79	258.03	312.38	510.69	163.98	109.04
Other Current Liabilities	4.45	81.08	2.54	3.03	613.57	573.72
Total Current Liabilities	869.52	1,004	809.84	1,110	4,167	3,445
Long-Term Leases	47.3	44.04	84.91	5.51	41.29	1.25
Long-Term Unearned Revenue	68.05	72.94	64.6	64.74	10.68	10.68
Total Liabilities	984.87	1,121	959.34	1,180	4,219	3,457

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	233.19	233.19	227.27	219.2	107.37	107.37
Retained Earnings	-4,317	-4,705	-4,323	-4,056	-3,482	-2,866
Comprehensive Income & Other	9,421	9,339	7,404	6,167	148.63	114.83
Shareholders' Equity	5,337	4,867	3,309	2,329	-3,226	-2,644
Total Liabilities & Equity	6,322	5,989	4,268	3,510	993.15	812.96

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	81.35	88.44	126.75	59.92	3,014	2,391
Net Cash (Debt)	4,696	4,383	2,942	2,428	-2,921	-2,309
Net Cash Growth	7.14%	48.99%	21.15%	-	-	-
Net Cash Per Share	20.13	19.01	13.27	13.22	-30.58	-24.98
Filing Date Shares Outstanding	233.19	233.19	227.27	219.2	215.83	92.46
Total Common Shares Outstanding	233.19	233.19	227.27	219.2	107.37	92.46
Working Capital	4,643	4,144	2,683	1,697	-3,835	-3,147
Book Value Per Share	22.89	20.87	14.56	10.63	-30.05	-28.60
Tangible Book Value	5,337	4,866	3,306	2,328	-3,229	-2,644
Tangible Book Value Per Share	22.89	20.87	14.55	10.62	-30.08	-28.60
Buildings	-	303.68	294.1	294.4	-	-
Machinery	-	398.76	324.51	262.26	221.56	200.16
Construction In Progress	-	97.28	88.11	119.99	348.59	282.36
Leasehold Improvements	-	16.6	16.47	14.45	13.67	0.38

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 21, 2026

Data Sources Report a data error